US EditionDepression spray to be cheaper for Aussie patients
- A ketamine-based nasal spray, Spravato, will be subsidized in Australia, making it more accessible for those with treatment-resistant depression starting May 1.
- Clinical psychiatrist Colleen Loo stated that further government subsidies are necessary for treatment accessibility, saying, 'The introduction of ketamine as a new treatment for treatment-resistant depression is really transformative.'
- Patients noted that even with Pharmaceutical Benefits Scheme coverage, they will still encounter additional costs for treatment administration.
- About one in seven Australians suffer from depression, with one in three experiencing treatment-resistant depression, according to health experts in the field.
Insights by Ground AI
Does this summary seem wrong?
18 Articles
18 Articles
All
Left
8
Center
Right
4
Depression treatment funding breaks 30-year drought
The federal government is set to fund a new type of medicine for major depression. (Lukas Coch/AAP PHOTOS) By Samantha Lock A mind-altering medication chemically akin to ketamine will be made cheaper to improve the lives of Australians suffering from treatment-resistant depression – the first new government-backed initiative to treat the chronic mental illness in decades. The drug – which comes in the form of a nasal spray – is a chemical cousin…
·Canberra, Australia
Read Full ArticleCoverage Details
Total News Sources18
Leaning Left8Leaning Right4Center0Last UpdatedBias Distribution67% Left
Bias Distribution
- 67% of the sources lean Left
67% Left
L 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium
